Selatogrel

From WikiProjectMed
Jump to navigation Jump to search
Selatogrel
Clinical data
Other namesACT-246475
Legal status
Legal status
  • Investigational
Identifiers
  • [(2R)-3-(4-Butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H39N6O8P
Molar mass618.628 g·mol−1

Selatogrel is a P2Y12 inhibitor[1][2] that has been proposed as a treatment for acute myocardial infarction.[3]

References

  1. ^ Milluzzo, Rocco P.; Franchina, Gabriele A.; Capodanno, Davide; Angiolillo, Dominick J. (June 2020). "Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development". Expert Opinion on Investigational Drugs. 29 (6): 537–546. doi:10.1080/13543784.2020.1764533. ISSN 1744-7658. PMID 32396484.
  2. ^ Parker, William A. E.; Storey, Robert F. (2020-01-02). "Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y 12 receptor antagonist". Expert Opinion on Emerging Drugs. 25 (1): 1–6. doi:10.1080/14728214.2020.1729121. ISSN 1472-8214. PMID 32064955.
  3. ^ Gehin, Martine; Storey, Robert F.; Bernaud, Corine; Dingemanse, Jasper (2023). "Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction". Expert Opinion on Drug Metabolism & Toxicology. 19 (10): 697–708. doi:10.1080/17425255.2023.2266384. ISSN 1744-7607. PMID 37795868.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Selatogrel"